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Abstract
Background: Herpes Simplex Virus type 2 (HSV-2) has public health importance as a leading cause of genital
ulcers, a co-factor in HIV-1 acquisition and transmission and as a cause of neonatal herpes infections. Little is
known of its epidemiology and burden in Coastal Kenya.
Methods: We screened plasma samples for HSV-2 infection from 826 women aged 15-34 years who participated in
an HIV-1 survey in Kilifi in 2004. The sample comprised 563 women selected randomly from a demographic
surveillance system (DSS) and 263 women who presented for voluntary counseling and testing (VCT). Predictors for
HSV-2 seropositivity were determined using multivariate logistic regression. The incidence of HSV-2 infection and
risk of neonatal herpes were estimated by a simple catalytic model fitted to age-seroprevalence data.
Results: HSV-2 prevalence was 32% in the DSS recruits vs. 44% in the VCT recruits (P < 0.001), while, HIV-1
prevalence was 8% in the DSS recruits vs. 12% in the VCT recruits (P = 0.12). Independent risk factors for HSV-2
infection in all women were: older age (30-34 years; odds ratio (OR) 10.5, 95% confidence interval (CI): 5.2 - 21.0),
recruitment from VCT (OR 1.5, 95% CI: 1.1 - 2.1), history of genital ulcers (OR 1.7, 95% CI: 1.2 - 2.3) and HIV infection
(OR 2.7, 95% CI: 1.6-4.6). Education beyond primary (OR 0.7, 95% CI: 0.5 - 0.9) was inversely associated with HSV-2
infection. In the DSS sample, HSV-2 incidence was estimated at 4 cases (95% CI: 3.3 - 4.4) per 100 women per year,
17 cases (95% CI: 16-18) per 1,000 pregnancies per year and 33 neonatal cases (95% CI: 31-36) per 100,000 births
per year.
Conclusions: HSV-2 transmission is rapid following the onset of sexual activity and likely to result in a significant
burden of genital ulcer disease. Nevertheless, the burden of neonatal HSV-2 can be predicted to be low. Educating
young women about HSV-2 infection may help in reducing its burden in this semi-urban population.
Background
Herpes Simplex Virus type 2 (HSV-2) infection among
women of the general population worldwide is of con-
siderable public health importance as a leading cause of
genital ulcer disease [1,2], neonatal herpes infections
[3-6] and due to its role in enhancing HIV-1 acquisition
and transmission [7-9].
Establishing the burden of HSV-2 infection can be dif-
ficult because incident cases and reactivations are often
missed clinically [6,10,11], and vertical transmission is a
rare occurrence in populations with low HSV-2 preva-
lence [12-15]. About 80% of neonatal herpes infections
arise from primary genital HSV-2 infection, acquired
late in pregnancy [3,5,6,15], and can result in significant
morbidity to the newborn child [4-6]. Reactivated HSV-
2 infections are estimated to cause <5% of neonatal
herpes transmission [5,15]. Neonatal herpes infections
can also be caused by HSV-1 infection in about 20% of
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the instances [5,15]. In the USA, neonatal herpes inci-
dence has been estimated as 1 case per 3200 live births
in a study involving over 58000 live births born in the
period 1982-1999 [3]. In Africa, there is no information
on the proportion of pregnant women who acquire HSV
during pregnancy or on the incidence or prevalence of
neonatal HSV-2 infection[16].
Studies in the African continent have shown variation
in HSV-2 prevalence across diverse populations of
women, ranging from 22% among adults in Tanzania
and 68% among adults in urban Kenya to 90% among
commercial sex workers in Zaire [9,17]. In Western
Kenya, an HIV survey among women aged 13-34 years
conducted in 2003-4 revealed an HSV-2 prevalence of
53% [18]. A more recent National AIDS Indicator survey
among general population women aged 15 - 64 years
estimated HSV-2 prevalence of 42% but data on the
possible impact of maternal transmission of HSV-2 were
not provided in that survey [19]. Prevalence data, how-
ever, provide information on the proportion of indivi-
duals infected and allow for an estimation of HSV-2
incidence. Hence, vertical transmission can be inferred
[3,14,15].
In this study we explore the prevalence of and predic-
tors associated with HSV-2 seropositivity, the estimated
rate of infection and the potential risk of vertical trans-
mission using two sample sets from within a well-enum-
erated population of semi-urban women from coastal
Kenya, namely, (i) a random sample of the adult women
population and (ii) self-selected women attending for
voluntary counselling and testing (VCT).
Methods
Kilifi District is a largely rural district in Coastal Kenya,
with an estimated population of 544,305 people (52%
female)[20]. In the year 2000, the Kenya Medical
Research Institute (KEMRI) - Wellcome Trust Research
Programme defined and mapped a geographical area in
Kilifi District for demographic surveillance and clinical
and epidemiological research. The resultant Kilifi Demo-
graphic Surveillance System (DSS) monitors a popula-
tion of around 240,000 residents [21]. Kilifi District has
a birth rate of approximately 8,000 live births per year,
perinatal mortality of 44 per 1000 live births [21] and
about 4,000 women attend antenatal care at the district
hospital per year [21]. Until 2003, in Kilifi, pregnant
women were not routinely tested for HIV-1, and VCT
services were not widely available. In 2004, a large HIV-
1 survey was conducted at several semi-urban commu-
nities in and around Kilifi town and VCT services were
strengthened.
In this study, we used data and serum samples of
women aged 15-34 years who were participants of the
2004 HIV-1 survey and resided in Kilifi and Mtondia
towns[21]. Kilifi and Mtondia areas are considered semi-
urban, as they are not densely populated, have few
paved roads and very few people have electricity.
Study participants were recruited (a) from the registers
of the DSS by simple random sampling or (b) as they
presented to a VCT-clinic supported by the study. The
DSS participants were visited by local fieldworkers in
their homes during daytime for recruitment into the
HIV-1 study. Overall non-participation was approxi-
mately 30%, as has previously been reported when the
DSS register is used for population sampling[22]. Non-
participation was predominantly caused by women who
were not present at the time of visiting the household.
No records of refusal were kept for non-respondent
women.
At recruitment, all volunteers were interviewed, coun-
selled and educated about the HIV prevalence study
prior to enrolment. Acceptance of HIV-1 testing was an
enrolment criterion. All volunteers gave informed con-
sent for storage of their blood samples and for more
testing of those samples on other infections related to
HIV. A survey questionnaire was administered through
one on one interview for collection of data on socio-
demographic characteristics, sexual exposure, medical
history and knowledge of sexually transmitted disease
(STD) / HIV-1 related infections. A medical history that
focused on the past or present STDs was obtained.
Medical care for prevalent sexually transmitted diseases
was provided. Volunteers received pre- and post-HIV
test counselling, and were tested for HIV-1 at the enrol-
ment visit using two rapid test kits (Determine, Abbott
Laboratories, Abbott Park, Illinois, USA; Unigold, Tri-
nity Biotech plc, Bray, Ireland) in parallel. Discrepant
rapid HIV-1 test results were resolved using an ELISA
test (Genetic System HIV-1/2 plus O EIA, Bio-Rad
Laboratories, Redmond, Washington, USA). Women
who tested HIV-1 positive were offered a pregnancy test
and referred for comprehensive HIV care, including Pre-
vention of Mother to Child Transmission (PMCTC) ser-
vices, as appropriate, at the District Hospital.
After testing for HIV-1, serum samples were stored
for other tests related to HIV-1 infection. The Kenya
National Ethical Review Committee approved this study.
Determination of HSV-2 antibody status
Approximately 10 ml of blood was collected from each
study participant, and the serum was stored at -70°C.
HSV-2 specific antibody status was determined for
serum samples using the HerpeSelect 2 ELISA IgG
(Focus Diagnostics, Cypress, California, USA) according
to the manufacturer’s protocol [23] with the following
exception. The protocol recommends a cut off index
value of 1.1 to determine HSV-2 infection. Due to a
lower specificity of the HerpeSelect test on serum
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samples from African populations, we used a cut off
value of > 3.5 to determine HSV-2 prevalence and inci-
dence estimates [24-26].
Statistical analyses
(i) Analysis of predictors of HSV infection
We conducted the analyses using STATA version 10
(StataCorp, College Station, Texas, USA). Chi-squared
and Fisher’s exact tests were used to determine univari-
ate associations with prevalent HSV-2 infection. Multi-
variate logistic regression was used to identify
independent predictors of HSV-2 seropositive status.
Variables were introduced sequentially into a multivari-
ate model, beginning with those with the strongest uni-
variate association (lowest p values) and including only
those which provided a significantly improved fit to the
data (a likelihood ratio test, LRT, P < 0.05). The correla-
tion coefficient between two variables was used to deter-
mine whether to exclude a variable from analysis due to
excessive colinearity (i.e., r2 > 0.2).
(ii) The risk of primary maternal and neonatal HSV-2
infection
The incidence of maternal HSV-2 infection and risk of
neonatal herpes were estimated using a simple catalytic
model as described in [27]. In this model, the force of
infection (i.e. per person incidence) was calculated by
fitting age-stratified prevalence of specific antibodies to
an exponential decay model by maximum likelihood.
The assumption was made that seronegative status
equates to the absence of HSV-2 infection (past or pre-
sent), and that following infection there was no rever-
sion to seronegativity. In other words we assumed the
seronegative status is equated with being susceptible to
infection. We further assumed that all women were ser-
onegative at age 14 years and thereafter exposed to a
force of infection (per year), l, constant across all ages
and unchanging over time (where l > 0). Hence the
proportion susceptible, s (a), at age a can be defined as
s(a) = exp
[−λ(a − 14)] , (1)
where 14 <a < 35. The proportion seropositive at age
a, p(a), is therefore 1-s(a). We fit this model by maxi-
mum likelihood to our observed proportions remaining
seronegative, S(i), representing r(i) seronegative indivi-
duals out of n(i) sampled for each single year of volun-
teer age, i = 15-34, to identify the value of the force of
infection best supported by the data and estimate the
95% confidence intervals [27].
We made the assumption that the force of infection
acting on pregnant women is equivalent to that esti-
mated from our seroprevalence survey. If we now
assume that the childbearing age range is 15-44 years,
with average proportion susceptible s¯ derived from (1),
and given a gestation period of 40 weeks, it follows that
the average annual risk of primary maternal HSV-2
infections per pregnancy, Im, is
Im = s¯
[
1 − exp(−λ40/52)] , (2)
which for small l approximates to
Im = s¯λ40/52. (3)
Assuming vertical HSV-2 infection only arises if a
pregnant woman is shedding virus at the time of birth
[6], that is, only for a primary or initial HSV-2 infection
during the final 11 days of pregnancy [28], and that this
transmission risk, v, is 50% [5,15], then from equation
(3) the risk of neonatal HSV per pregnancy,In, is
In = s¯λ11
/
365v. (4)
The number of maternal infections per 1,000 pregnan-
cies and neonatal infections per 100,000 live births can
thus be defined from equations (3) and (4), respectively;
the latter assuming there is no excess mortality attribu-
table to HSV-2 infection.
Results
The sample comprised 826 women of median age 24
years (Interquartile range (IQR): 15-34 years), of whom
563 (68%) were selected by random sampling from the
DSS (median age of 24 years; IQR 21-29), and 263
(32%) were individuals presenting to the VCT-clinic
(median age 24 years; IQR 21-28). Details of demo-
graphic characteristics of these women in the two
groups (DSS and VCT participants) are given in (Table
1).
The two sampling groups differed in their marital sta-
tus and religion (Table 1). Women attending VCT,
when compared to the random sample from the DSS,
were more likely to have used condoms, to have had
casual sexual relationships, had more sexual partners in
the previous year, and also to have genital ulcers (either
presently or ever). The two groups did not differ signifi-
cantly in HIV-1 prevalence (12% in VCT vs. 8% in DSS,
P = 0.12), ethnic composition, educational level attained,
or age distribution. There was a higher seroprevalence
of HSV-2 in VCT-women compared with DSS-women
(44% (115/263) vs. 32% (181/563), P < 0.001). Of 77
HIV-1 positive women, 50 (65%) were HSV-2 positive,
compared to 33% (246/749) of HIV-1 negative women
(p = 0.001).
Predictors of HSV-2 seropositivity
Significant associations from univariate analysis are
detailed in Table 2. The probability of being HSV-2
seropositive was significantly higher in women who
were of older age, were sampled from the VCT clinic,
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were ever married, were less educated, had causal part-
ners in the last year, had ever had genital ulcers, or
were HIV-1 antibody positive. Marital status was cor-
related (r2>0.2) with multiple factors (including educa-
tional status, HIV-1 status, religion, use of condoms
and history of genital ulcers) and was dropped from
further analysis. Factors shown to be independently
associated with HSV-2 sero-positivity using multivari-
ate logistic modelling are shown in Table 3. HSV-2
positive status was found to be associated with increas-
ing age, recruitment from the VCT centre, history of
genital ulcers and positive HIV-1 sero-status. Higher
educational level was inversely associated with HSV-2
seropositivity. Separate multivariate models for DSS
and VCT women were developed, which gave similar
results to those of the full model, except that for DSS
women the association with present genital ulcers was
replaced with ever having had genital ulcers, and for
Table 1 Characteristics of participating women from Kilifi, Kenya
Characteristic DSSμ % VCTa % Total % P*
Sample size 563 263 826
Age, years
Median (range) 24 (15-34) 24(18-34) 24(15-34) 0.536^
15-19 105 19 30 11 135 16 0.001
20-24 179 32 118 45 297 36
25-29 142 25 67 25 209 25
30-34 137 24 48 18 185 22
Marital status
Single 172 31 70 27 242 29 0.002
Married monogamous 314 56 129 49 443 54
Married polygamous 36 6 26 10 62 8
Widow/separated 41 7 38 14 79 10
Education
Completed primary 247 44 119 45 366 44 0.764
Religion
Christian 325 58 183 70 508 62 0.005
Muslim 135 24 46 17 181 22
Other 103 18 34 13 137 17
Ethnicity
Giriama 375 67 171 65 546 66 0.128
Chonyi 60 11 19 7 79 10
Other 128 23 73 28 201 24
Condomuse sometimes
Yes 74/419 18 74/228 32 148/647 23 <0.001
Casual partners in last year
Yes 66/428 15 49/158 31 115/586 20 <0.001
Partners in last year
None 238/429 55 93/158 59 331/587 56 <0.001
One 162/429 38 39/158 25 201/587 34
More than one 29/429 7 26/158 16 55/587 9
History genital ulcer
Yes 161 29 114 43 275 33 <0.001
Genital ulcer now
Yes 56/479 12 45/258 17 101/737 14 0.033
HIV status
Pos 46 8 31 12 77 9 0.122
HSV-2 status (>3.5 cut off)
Pos 181 32 115 44 296 36 <0.001
μDSS - Demographic Surveillance System
aVCT - Voluntary Counselling and Testing.
*P - Chi squared P value
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VCT women the association with casual partners in
the last year was lost. In the full model no factors sig-
nificantly interacted with the association between study
group (DSS vs. VCT) and HSV-2 status.
Incidence estimates of maternal HSV-2 infection and
estimated risk of neonatal herpes
The proportions of HSV-2 seronegative women
recruited from the DSS declined from 94% in those
aged 15-19 years to 47% in those aged >30 years. The
corresponding proportions for VCT-women were 83%
and 48%. In 30 DSS-women aged 15-16 years only 3%
were HSV-2 seropositive. The fit of the maximum likeli-
hood catalytic models to proportions seronegative by
age and by source of recruitment (DSS or VCT) are
shown in Figure 1. The estimated incidence of HSV-2
infection was 3.8 (95% CI: 3.3-4.4) per 100 seronegative
women per year for DSS-participants (Table 4) and 5.7%
(95% CI 4.7-6.8) per year for VCT participants.
Using estimates of the force of infection acting on
women in the DSS, we estimate an average proportion
seronegative of 58.6% (95% CI: 54.4-62.8) over the child-
bearing age. Hence the estimated incidence of maternal
infections derived from Equation 3 is 17.1 (95% CI:
15.7-18.3) cases per 1,000 pregnancies per year, and the
estimated incidence of neonatal transmission derived
from Equation 4 is 33 (95% CI: 31-36) per 100,000 preg-
nancies per year (Table 4).
Discussion
In this study we describe the serological epidemiology of
prevalent HSV-2 infection among women of the semi-
urban population of Kilifi, coastal Kenya, who were pre-
sumed to be either a relatively low risk group for HIV
infection randomly selected from within a population
Table 2 Risk factors for HSV-2 in semi-urban women in
Kilifi, Kenya: univariate analysis
HSV2 95%CI
Characteristic pos n % OR LCL UCL P
Age, years
15-19 (ref) 11 135 8.1
20-24 98 297 33.0 5.6 2.9 10.8 <0.001
25-29 90 209 43.1 8.5 4.3 16.7 <0.001
30-34 97 185 52.4 12.4 6.3 24.5 <0.001
Study group
DSS (ref) 181 563 32.1
VCT 115 263 43.7 1.6 1.2 2.2 <0.001
Marital status
Never married (ref) 42 242 17.4
Married monogamous 173 443 39.1 3.1 2.1 4.5 <0.001
Married polygamous 33 62 53.2 5.4 3.0 9.9 <0.001
Ever married 48 79 60.8 7.4 4.2 12.9 <0.001
Education
None or some primary (ref) 183 460 39.8
Completed primary 113 366 30.9 0.7 0.5 0.9 <0.008
Religion
Christian (ref) 160 508 31.5
Muslim 75 181 41.4 1.5 1.1 2.2 0.016
Other 61 137 44.5 1.7 1.2 2.6 <0.005
Ethnicity
Giriama (ref) 190 546 34.8
Chonyi 26 79 32.9 0.9 0.6 1.5 0.742
Other 80 201 39.8 1.2 0.9 1.7 0.207
Condom use
Never (ref) 209 499 41.9
At least sometimes 50 148 33.8 0.7 0.5 1.0 0.078
Casual partners in last year
No (ref) 179 471 38.0
Yes 57 115 49.6 1.6 1.1 2.4 0.024
Number of partners in last
year
None (ref) 143 331 43.2
One 68 201 33.8 0.7 0.5 1.0 0.033
More than one 26 55 47.3 1.2 0.7 2.1 0.573
History genital ulcer
No (ref) 158 551 28.7
Yes 138 275 50.2 2.5 1.9 3.4 <0.001
Genital ulcer now
No (ref) 229 636 36.0
Yes 61 101 60.4 2.8 1.8 4.5 <0.001
HIV status
Negative (ref) 246 749 32.8
Positive 50 77 64.9 3.8 2.3 6.2 <0.001
Table 3 Risk factors for HSV-2 in semi-urban women in
Kilifi, Kenya: multivariate analysis (n = 826)
95%CI
Characteristic ORa LCL* UCL* P
Age, years
15-19 (ref)
20-24 4.7 2.4 9.2 <0.001
25-29 6.9 3.5 13.7 <0.001
30-34 10.5 5.2 21.0 <0.001
Study group
DSS (ref)
VCT 1.5 1.1 2.1 0.010
Education
None or some primary (ref)
Completed primary 0.68 0.50 0.94 0.018
History of genital ulcer
No (ref)
Yes 1.7 1.2 2.3 0.002
HIV status
Negative (ref)
Positive 2.7 1.6 4.6 <0.001
aOR, Odds Ratio,*LCL, UCL, Lower and upper 95% confidence interval,
respectively
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under demographic surveillance or a self-selected pre-
sumed higher risk group for HIV infection recruited
from a VCT-centre. Our aims were to characterize pre-
dictors of prevalent HSV-2 infection, estimate incidence
of maternal HSV-2 infection within this population, and
hence, indirectly, estimate the potential neonatal disease
burden.
Overall, HSV-2 prevalence in DSS-women and VCT-
women aged 15-34 years, at 32%, and 44%, respectively,
is in the same range of the 42% national prevalence
reported among Kenyan women from 15-64 years of age
[19]. Similar to other studies, we found a rapid rise in
HSV-2 seroprevalence from mid-late teenage years
upwards coincident with onset of sexual activity [29].
Consistent with results of the national survey[19], we
observed that HSV-2 prevalence increases with age.
Analysis of factors associated with prevalent HSV-2
infection suggests a small but significantly higher pro-
portion of women attending VCT with HSV-2 compared
with the general population women selected through the
DSS. However, the nature of the factors associated with
prevalent HSV-2 infection in multivariate analysis
appeared largely the same between the two groups.
Positive HIV-1 status was the strongest independent
predictor of HSV-2 seropositivity, as reported elsewhere
[29,30]. HIV-1 infection increases the risk of acquisition
0
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Figure 1 Age-stratified proportions HSV-2 seronegative by age (years) and by study group for semi-urban women from Kilifi, coastal
Kenya. Data are shown for a random sample from the demographic surveillance system, DSS (filled marker) and a sample attending the VCT
clinic (open marker). The corresponding best fit catalytic model curves (solid for DSS and dashed line VCT) are based on maximum log likelihood
estimates (MLE) of the HSV-2 force of infection ( 95% CL, MLE) of 3.8% per annum (3.3-4.4, -319.532) in DSS women and 5.7% per annum (4.7-
6.8, -168.233) in VCT women respectively.
Table 4 The estimated incidence of maternal and neonatal HSV-2 transmission in a random sample of 563 resident
semi-urban women from Kilifi, Kenya
Force of infection(/100
susceptible$ women per year)
Estimated proportion
susceptible (%)
Incidence of maternal infection
(/1000 pregnancy per year)
Incidence of neonatal transmission
(/100,000 births per year)
Estimate 3.8 58.6 17.1 33
LCL* 3.3 54.4 15.7 31
UCL 4.4 62.8 18.3 36
*LCL, UCL Lower and upper 95% confidence interval, respectively
$ It is assumed that seronegative status equates with susceptibility
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of HSV-2, the frequency and severity and reactivations
[31,32]. Other variables associated with sexually trans-
mitted diseases were also independently associated, but
less strongly, with HSV-2 infection, including the pre-
sence of genital ulcers and having had a casual partner
in the preceding 12 months.
Education beyond primary school (greater than year 8
in Kenyan schools), with a prevalence of 45% in this
sample, was found to be inversely associated with HSV-
2, with ~1.5 fold reduced likelihood of seropositivity.
Similarly, a separate study has found that not finishing
primary school was a significant predictor of HSV-2 pre-
valence among 469 women enrolled for an at-risk
cohort of HIV-1 infection from nearby coastal areas
[33]. Although education attainment has been inconsis-
tently associated with HSV-2 sero-prevalence in prior
studies [29,34,35], knowledge of HSV-2 infection among
women in similar parts of East Africa has been very low
[36]and the development of reproductive education pro-
grams, within the school curriculum, to increase aware-
ness of HSV-2, is an intervention activity worth
undertaking in Kenyan schools.
Using data from our prevalence study, we estimated
the incidence of vertical transmission of HSV-2. The
catalytic model we used was computed on the assump-
tions that HSV-2 shedding during delivery as a result of
primary HSV-2 infection has a 50% risk of neonatal
HSV-2 acquisition [5,15], and the risk of a baby acquir-
ing HSV-2 from an infected mother occurs at primary
infection within 11 days [28] (the average duration of
viral shedding) of delivery [3,6,37]. Kilifi has a birth rate
of 8000 live births per year [21], hence it is estimated
that about 3 cases of neonatal herpes will occur per year
among pregnant women in this population.
Earlier studies in Kilifi, assumed that the large number
of perinatal deaths, especially those occurring at home,
where cause could not be established, may have been
related to HIV and sexually transmitted infections
[21,38]. However, our data suggests that the burden of
neonatal HSV-2 disease from maternal transmission is
low and contributes insignificantly to the observed neo-
natal deaths in this region.
Interestingly, our estimate of the incidence of neonatal
herpes is similar to the estimate of 1 case per 3200 live
births from the USA [3]. However, most births in Kilifi
district occur at home and options for appropriate inter-
ventions while mothers experience acute HSV-2 infections
prior to birth are very limited. Where possible, prevention
programmes aiming to reduce the burden of HIV-1 infec-
tions in women need to include information on HSV-2
infection. Pregnant women should be counselled to use
condoms and avoid unprotected oral-genital contact dur-
ing the last trimester of pregnancy and be advised to
report to a referral health facility when signs of genital
herpes infection are noted prior to delivery [14].
There are several limitations to this study. First, dur-
ing the 2004 HIV-1 survey, records of women refusing
participation in the HIV-1 survey were not kept. There-
fore, we were unable to establish whether individuals
who refused and those who participated in the study dif-
fered in characteristics. Second, this was a cross sec-
tional study restricted to women only. Hence, the
analysis of predictors of prevalent HSV-2 infection only
established associations and could not make causal
inferences. Third, we did not conduct any biological
measurements of other common sexually transmitted
diseases (e.g. syphilis) or perform visual inspection for
the presence of genital ulcers. Lastly, we based our cata-
lytic model on assumptions that HSV-2 incidence is
independent of age (or time), even though, the risk for
HSV-2 infection increases with age. In this study,
including age-dependence in the rate of infection did
not significantly improve the model fit. Furthermore,
the data appear to follow a linear cumulative hazard
from which we deduced that there was no good evi-
dence for age (or time) dependence in HSV-2 incidence.
We also, may have underestimated the burden of neona-
tal herpes infection as HSV-2 acquisition due to reacti-
vated HSV-2 infections were not included in the model
(considered to have less than 5% risk of neonatal herpes
infections transmission), and HSV-1 infections in this
study population were not measured.
Conclusions
In summary, the existing burden of HSV-2 infection in
the Kilifi semi-rural population is similar to national
HSV-2 prevalence estimates in Kenya. HSV-2 transmis-
sion is rapid following the onset of sexual activity.
Women infected with HSV-2 have an increased risk of
acquiring HIV-1, and HSV-2 infection may remain a
driving force behind the HIV-1 epidemic in this semi-
urban population. Mother to child herpes transmission
is unlikely to be a significant public health problem in
this population. Educating young women about HSV-2
infection may help in reducing its burden in this semi-
urban population.
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